Finally, we validated Pax5 expression in tissue microarrays (TMAs) derived from prostate cancer patient-derived xenografts (PDX) (LuCaP series) and from metastatic CRPC (mCRPC) tissues obtained from Prostate Cancer Biorepository Network (PCBN). This evidence concerns the gene PAX5 and prostate carcinoma.